Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. - Wikidata - wikimedia - TriplyDB

Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.

Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.

http://www.wikidata.org/entity/Q36615576

about

Current and emerging strategies for the prevention of graft-versus-host disease Advances in predicting acute GVHD Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement Current and future approaches for control of graft-versus-host disease.The biology of graft-versus-host disease: experimental systems instructing clinical practice.Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials.Pathogenesis and management of graft-versus-host disease.Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation.Recent advances in the management of graft-versus-host disease.Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.Tumor necrosis factor is critical for cytolytic T cell activity against allospecific hepatocytes and splenic targets in major histocompatibility complex class I disparate graft versus host disease.Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids.Management of acute graft-versus-host disease in children.Unsuccessful treatment of four patients with acute graft-vs-host disease after liver transplantation.First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.Have we improved in preventing and treating acute graft-versus-host disease?Implications of TNF-α in the pathogenesis and management of GVHD Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival.Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients.A biomarker panel for acute graft-versus-host disease Advances in the treatment of acute graft-versus-host disease.Biomarker Panel for Chronic Graft-Versus-Host Disease.Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease.Acute graft-versus-host disease: from the bench to the bedside.Emerging drugs for acute graft-versus-host disease.Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.Acute graft-versus-host disease: new treatment strategies.Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.Progress and prospects: graft-versus-host disease.Suicide gene therapy for graft-versus-host disease.Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.

P2860

Q27016541-EA8791A8-D678-4B1E-9AF4-FCFE422768EC Q27021123-41FBD9FB-B6DD-461F-8DE5-745A1D19FCEB Q33622648-36B3E3FD-1970-4F65-8D29-C9355236B5F6 Q33642625-04868437-B612-4411-B624-396458E8BC4D Q33917175-9D18BDDF-FC58-4F9C-91BD-CA90647AD1B3 Q33971524-9F713874-6EE2-415E-9F04-8764A2C3BB34 Q34077479-9BC3B185-1E10-4F61-AE16-0A76AC19915B Q34093615-3CE3F529-4E3B-4F2A-A28A-C68E7A19FFBE Q34184622-14BEBAD6-849E-4C22-BEB7-D48FB6D2E5FB Q34428890-C492D5FD-00E2-4D41-B6A0-D0C318494DF9 Q34487408-8FDAED97-452B-4705-81C3-BFDEA18AFB99 Q34607576-D3550D0E-7FDF-4C99-B9F6-4BF620E406CF Q34875248-21E1385C-0963-472C-9F54-C4A275E1CDB4 Q35193740-07C18688-E98F-479E-A62F-F6FFEF837A36 Q35583009-BF413EC2-D83B-4234-B6E4-6E50040ED3FE Q35653617-57AABF84-284D-4A13-83AB-53C75AA68B1F Q36113205-B6D79581-060F-4EB9-B7E6-31952BC9A417 Q36203692-3EA60F06-EEB0-459F-8783-6D5E221F5F26 Q36370782-90477C0E-F0F0-43BA-BEC8-838919902024 Q36408216-53294096-61C6-4B2C-9285-1A0996FD73EA Q36821646-2D0530A1-2939-44DE-9890-9BDE2F28CA1D Q36835126-CD4EFB3F-2090-4D75-85F4-A828FCBBDA17 Q36868082-C4DCD754-B151-431F-B9D8-BBDB1601DA2E Q36891433-3DAE6BCB-5352-4330-BA0C-E1C9037933C8 Q36961081-03C860EC-58D2-4494-8441-D204DA6AD7EE Q37041904-B20CE6EB-0784-40B5-B216-CBCE258E582B Q37191057-4FBF2D72-30E8-422A-98DE-28A6C7559A44 Q37234820-A4E2B866-C6D7-4FC1-85E6-43FFA652AF97 Q37268948-6DFD9DFD-5CBF-4E24-AB56-8B4BC5B8E72D Q37414672-56C4439B-0F74-44EE-8F96-5B4E62C2CFB7 Q37420496-908DCADB-8DAA-48CD-8DE9-BF4E3C98EE8B Q37515433-B363FBCD-35B9-4BA1-878C-89FCE6F5BA2E Q37535273-1657F525-98E0-4E06-8F19-630C8451B0C6 Q37610714-7CACBE53-A000-4EA4-A30D-31EEDC6B7846 Q37621636-8A4726E5-9A24-4A6F-B6F3-6272D9B0F8EC Q37635642-8BF03796-A07B-4B0B-A5A6-48EB41F21662 Q37761297-7B0346C1-E6BE-4BFD-85E5-EB1FDDD1BEFC Q37773293-1C2EEF14-CD55-4F0B-A31E-117AA39C665D Q37810286-CA44C831-76BB-4BC3-9C34-940215B53E8D Q37851519-5BB01AB6-62EC-4D42-9DF8-ACB1D37D067C

P2860

Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.

http://www.wikidata.org/entity/Q36615576

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Etanercept plus methylpredniso ...... ute graft-versus-host disease.

@ast

Etanercept plus methylpredniso ...... ute graft-versus-host disease.

@en

type

label

Etanercept plus methylpredniso ...... ute graft-versus-host disease.

@ast

Etanercept plus methylpredniso ...... ute graft-versus-host disease.

@en

prefLabel

Etanercept plus methylpredniso ...... ute graft-versus-host disease.

@ast

Etanercept plus methylpredniso ...... ute graft-versus-host disease.

@en

P1433

Q36615576-A9CDF9D1-FF2E-49B4-8B5C-6CF83649ABA3

P1476

Q36615576-9D18B7FC-FB41-410E-8989-F295125506C8

P2093

Q36615576-11DB0C75-B5C6-477B-9C9D-76014B5D676A

Q36615576-23A419AC-5BD3-423D-BC59-FE711D33D5DE

Q36615576-4464B82B-0C3F-4322-BDD6-7A5AB769D05B

Q36615576-54F52AEA-75CA-4069-9B37-0382F935E9DB

Q36615576-6840843E-E297-426C-8F23-23413C98BF0E

Q36615576-6F07662E-B1A3-4797-A28F-91FBBE0BEA43

Q36615576-79BF367B-0E2D-4423-8178-278FE833C476

Q36615576-861C3FA8-9125-4100-905E-A1E05233F3FF

Q36615576-CDAFFE77-22FD-4565-AF9C-95D79F40D647

Q36615576-D5C0BF01-C25B-4F1A-83D3-8315464FAB52

P2860

Q36615576-01099F37-2746-428A-A868-70E0FD0FF7E9

Q36615576-0C7C8FAD-7974-45E6-A07B-8639FD8F0D22

Q36615576-1511267C-0B6E-4AAA-847E-0E5CBA21834F

Q36615576-2450E6D1-728C-4031-A15C-4B17A31650D9

Q36615576-35FAD697-D0A0-498B-AEE8-DC8166FAE368

Q36615576-37E4BD95-E638-4B91-B7F2-37FA2EC11229

Q36615576-3851D72D-7B89-4A3C-A653-E6D4A8A19621

Q36615576-3BFE8EB3-AD59-4468-B6F7-77B3C0644A57

Q36615576-685D6953-9A95-4888-94A3-44380F1B8A73

Q36615576-7AE94CDB-8475-4DFA-84F1-366235C013F7

P304

Q36615576-38FE56A4-1BC2-4513-9193-DC482BA66355

P31

Q36615576-78972C59-DB45-445E-9960-0BD71269777D

P356

Q36615576-074F46C6-A1AF-48AD-9DA1-57DE49386486

P407

Q36615576-57C7CE83-DCCD-4A5F-AC7B-29C30741D688

P433

Q36615576-44D78455-2532-4442-97A0-2462EE2E4537

P478

Q36615576-9C086687-9CDB-4B47-A115-4D0686E86072

P50

Q36615576-99D5288D-2D16-458A-A45D-AFBE8B4CDB14

P577

Q36615576-B66F57D8-8189-42F7-ABB7-FDDFF59223E0

P5875

Q36615576-C66299D3-D735-4DB7-95DA-13A4652D977F

P698

Q36615576-7CC49B93-9EC8-4854-956C-A57E0DBB32EC

P932

Q36615576-4EAA7930-4CA4-40B7-A0A5-A86886D6561E

P356

BLOOD-2007-09-112987

P1433

P1476

Etanercept plus methylpredniso ...... ute graft-versus-host disease.

@en

P2093

Carrie L Kitko

http://www.w3.org/2001/XMLSchema#string

Daniel Bickley

http://www.w3.org/2001/XMLSchema#string

Dawn Jones

http://www.w3.org/2001/XMLSchema#string

Gregory Yanik

http://www.w3.org/2001/XMLSchema#string

James L M Ferrara

http://www.w3.org/2001/XMLSchema#string

John E Levine

http://www.w3.org/2001/XMLSchema#string

Oleg Krijanovski

http://www.w3.org/2001/XMLSchema#string

Pavan Reddy

http://www.w3.org/2001/XMLSchema#string

Raymond J Hutchinson

http://www.w3.org/2001/XMLSchema#string

Shin Mineishi

http://www.w3.org/2001/XMLSchema#string

P2860

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Immunobiology of acute graft-versus-host disease.

Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity

Serious infections associated with anticytokine therapies in the rheumatic diseases.

Diverse effects of infliximab and etanercept on T lymphocytes.

Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease

Prophylaxis and treatment of acute graft-versus-host disease.

Etanercept: a review of its use in the management of rheumatoid arthritis.

An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens.

A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment.

P304

2470-2475

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-09-112987

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Sophie Paczesny

P577

2007-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5804703

http://www.w3.org/2001/XMLSchema#string

P698

18042798

http://www.w3.org/2001/XMLSchema#string

P932

2361693

http://www.w3.org/2001/XMLSchema#string